Hartford Investment Management CO Vertex Pharmaceuticals Inc Transaction History

Hartford Investment Management CO

$2.99 Billion
Q3 2024

A detailed history of Hartford Investment Management CO transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Hartford Investment Management CO holds 16,250 shares of VRTX stock, worth $8.16 Million. This represents 0.25% of its overall portfolio holdings.

Number of Shares

16,250

Previous 16,534 1.72%

Holding current value

$8.16 Million

Previous $7.75 Million 2.48%

% of portfolio

0.25%

Previous 0.27%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 22, 2024	SELL	$460.0 - $505.78 $130,640 - $143,641	-284 Reduced 1.72%	16,250 $7.56 Million
Q2 2024 Aug 01, 2024	SELL	$392.81 - $485.53 $47,530 - $58,749	-121 Reduced 0.73%	16,534 $7.75 Million
Q1 2024 Apr 17, 2024	SELL	$407.69 - $446.08 $285,790 - $312,702	-701 Reduced 4.04%	16,655 $6.96 Million
Q4 2023 Jan 23, 2024	SELL	$343.0 - $410.68 $122,108 - $146,202	-356 Reduced 2.01%	17,356 $7.06 Million
Q3 2023 Oct 16, 2023	SELL	$338.18 - $362.46 $158,606 - $169,993	-469 Reduced 2.58%	17,712 $6.16 Million
Q2 2023 Jul 19, 2023	SELL	$314.42 - $351.91 $1.09 Million - $1.22 Million	-3,476 Reduced 16.05%	18,181 $6.4 Million
Q1 2023 May 09, 2023	SELL	$283.23 - $323.1 $735,831 - $839,413	-2,598 Reduced 10.71%	21,657 $6.82 Million
Q4 2022 Jan 20, 2023	SELL	$285.76 - $321.48 $25,718 - $28,933	-90 Reduced 0.37%	24,255 $7 Million
Q3 2022 Nov 02, 2022	SELL	$273.83 - $305.53 $43,538 - $48,579	-159 Reduced 0.65%	24,345 $7.05 Million
Q2 2022 Jul 22, 2022	BUY	$234.96 - $292.55 $98,683 - $122,871	420 Added 1.74%	24,504 $6.91 Million
Q1 2022 Apr 20, 2022	SELL	$221.42 - $260.97 $379,071 - $446,780	-1,712 Reduced 6.64%	24,084 $6.29 Million
Q4 2021 Feb 02, 2022	BUY	$177.01 - $223.45 $284,101 - $358,637	1,605 Added 6.63%	25,796 $5.67 Million
Q3 2021 Nov 01, 2021	SELL	$181.39 - $202.99 $554,690 - $620,743	-3,058 Reduced 11.22%	24,191 $4.39 Million
Q2 2021 Jul 29, 2021	SELL	$187.49 - $221.1 $212,801 - $250,948	-1,135 Reduced 4.0%	27,249 $5.49 Million
Q1 2021 Apr 21, 2021	SELL	$207.02 - $241.31 $264,985 - $308,876	-1,280 Reduced 4.31%	28,384 $6.1 Million
Q4 2020 Feb 01, 2021	BUY	$207.01 - $276.09 $516,489 - $688,844	2,495 Added 9.18%	29,664 $7.01 Million
Q3 2020 Oct 29, 2020	SELL	$255.65 - $303.1 $237,754 - $281,883	-930 Reduced 3.31%	27,169 $7.39 Million
Q2 2020 Aug 04, 2020	BUY	$225.48 - $295.8 $47,801 - $62,709	212 Added 0.76%	28,099 $8.16 Million
Q1 2020 Apr 24, 2020	BUY	$199.77 - $247.81 $201,567 - $250,040	1,009 Added 3.75%	27,887 $6.64 Million
Q4 2019 Jan 29, 2020	SELL	$166.71 - $223.91 $110,695 - $148,676	-664 Reduced 2.41%	26,878 $5.89 Million
Q3 2019 Oct 28, 2019	SELL	$166.23 - $187.09 $43,552 - $49,017	-262 Reduced 0.94%	27,542 $4.67 Million
Q2 2019 Jul 25, 2019	BUY	$164.61 - $190.37 $28,477 - $32,934	173 Added 0.63%	27,804 $5.1 Million
Q1 2019 Apr 29, 2019	SELL	$163.73 - $194.7 $272,119 - $323,591	-1,662 Reduced 5.67%	27,631 $5.08 Million
Q4 2018 Feb 04, 2019	BUY	$151.91 - $192.21 $140,061 - $177,217	922 Added 3.25%	29,293 $4.85 Million
Q3 2018 Nov 08, 2018	SELL	$167.73 - $192.74 $278,431 - $319,948	-1,660 Reduced 5.53%	28,371 $5.47 Million
Q2 2018 Jul 19, 2018	SELL	$145.72 - $169.96 $2.83 Million - $3.3 Million	-19,440 Reduced 39.3%	30,031 $5.1 Million
Q1 2018 Apr 24, 2018	SELL	$151.6 - $177.13 $572,593 - $669,020	-3,777 Reduced 7.09%	49,471 $8.06 Million
Q4 2017 Feb 12, 2018	SELL	$137.28 - $155.55 $111,883 - $126,773	-815 Reduced 1.51%	53,248 $7.98 Million
Q3 2017 Nov 13, 2017	BUY	$148.13 - $162.24 $8.01 Million - $8.77 Million	54,063	54,063 $8.22 Million

Others Institutions Holding VRTX

# of Institutions

1,716

Shares Held

225M

Call Options Held

1.19M

Put Options Held

1.56M

View Full List

About VERTEX PHARMACEUTICALS INC

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $129B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

More about VRTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Hartford Investment Management CO, based on Form 13F filings with the SEC.

News

Stay updated on Hartford Investment Management CO with notifications on news.

Account

Hartford Investment Management CO Vertex Pharmaceuticals Inc Transaction History